🏛️ Verified NIH Record • Updated 2025-02-27
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer (NCT06005740)
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: TORL Biotherapeutics, LLC
🩺 Plain-English Summary (8th-Grade Level)
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Phoenix — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Mayo Clinic Phoenix — Phoenix, Arizona
- Providence Medical Foundation — Fullerton, California
- UCLA - JCCC Clinical Research Unit — Los Angeles, California
- Torrance Memorial Physician Network — Torrance, California
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Florida Cancer Specialists Lake Nona Drug Development Unit — Orlando, Florida
- Mayo Clinic Rochester — Rochester, Minnesota
- Virginia Cancer Specialists — Lexington, Virginia
- University Health Network, Princess Margaret Cancer Centre — Toronto, Ontario
- McGill University Health Centre — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (310) 348-9636
Email: caroline.labib@torlbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.